• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Vitiligo Could Be a Marker of Efficacy for Melanoma Drugs, Study Indicates

Article

The retrospective analysis conducted in stage 3 and 4 immunotherapy-treated melanoma patients found that the development of vitiligo could serve as a clinical marker for effective antimelanoma immunity and improved clinical outcome.

The development of vitiligo in melanoma patients on immunotherapy may predict improved survival, according to findings from a systematic review and meta-analysis.

In 137 studies reported between 1995 and 2013 and including 5737 patients with stage 3 to 4 melanoma who were treated with immunotherapy, the pooled cumulative incidence of vitiligo was 3.4%. In those with vitiligo for whom individual patient data were available, both progression-free and overall survival were significantly improved, compared with those without vitiligo after researchers adjusted for age and sex (hazard ratio, 0.51 and 0.25, respectively), Hansje-Eva Teulings, MD, of the University of Amsterdam and her colleagues reported online January 19 in the Journal of Clinical Oncology.

http://bit.ly/1t61cUe

Link to the complete article on Oncology Practice:

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.